Delivery Order SPE2DB24D2013-SPE2DB25FCJXZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 30 mg capsules (100-count units) on September 3, 2025, with a ceiling value of $1,176.88 and ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under a larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units) with a ceiling value of $11,578.87. This firm fixed-price delivery order, with an ultimate completion date of September 16, 2025, represents a non-competitive set-aside arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100 count) with a ceiling value of $2,031.40. This is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's capability to compete successfully in open federal procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) under a firm fixed-price contract valued at $11,279.96. This non-competitive delivery order is expected to be completed by September 2, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,883.72 for Lisdexamfetamine 30 mg capsules (100-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under the company's broader pharmaceutical supply arrangements with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Lisdexamfetamine 50 mg capsules (100-count units) with a ceiling value of $1,651.64. This competitively awarded, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lisdexamfetamine 50 mg capsules (90-count units) valued at $1,057.44. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive award practices. The delivery order is due for completion by September 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $2,587.33. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The order is set to complete by July 25, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100-count units) with a ceiling value of $1,931.32. This is a firm fixed price delivery order without set-aside designation, demonstrating competitive award of this pharmaceutical product. The order is scheduled for completion by June 30, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Lisdexamfetamine 20 mg capsules (100-count units) with a ceiling value of $4,221.50. This competitively awarded, firm fixed-price delivery order is set to be completed by August 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJXZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,137.22. This non-set-aside delivery order is scheduled for ultimate completion on August 19, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal healthcare systems, particularly those serving military and veteran populations. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The current award for lisdexamfetamine, a central nervous system stimulant commonly used in treating attention deficit hyperactivity disorder, reflects the ongoing federal procurement of essential medications through this blanket purchasing arrangement that consolidates medical supply chain operations across Department of Defense healthcare providers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/18/25 |